Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jun:96:82-90.
doi: 10.1016/j.ejca.2018.03.020. Epub 2018 Apr 18.

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study

N Nabieva  1 , T Fehm  2 , L Häberle  3 , J de Waal  4 , M Rezai  5 , B Baier  4 , G Baake  6 , H-C Kolberg  7 , M Guggenberger  8 , M Warm  9 , N Harbeck  10 , R Wuerstlein  10 , J-U Deuker  11 , P Dall  12 , B Richter  13 , G Wachsmann  14 , C Brucker  15 , J W Siebers  16 , M Popovic  17 , T Kuhn  18 , C Wolf  19 , H-W Vollert  20 , G-P Breitbach  21 , W Janni  22 , R Landthaler  23 , A Kohls  24 , D Rezek  25 , T Noesselt  26 , G Fischer  27 , S Henschen  28 , T Praetz  29 , V Heyl  30 , T Kühn  31 , T Krauss  32 , C Thomssen  33 , A Hohn  34 , H Tesch  35 , C Mundhenke  36 , A Hein  1 , C C Hack  1 , K Schmidt  37 , E Belleville  38 , S Y Brucker  39 , S Kümmel  40 , M W Beckmann  1 , D Wallwiener  39 , P Hadji  41 , P A Fasching  42
Affiliations
Observational Study

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study

N Nabieva et al. Eur J Cancer. 2018 Jun.

Abstract

Background: Endocrine treatment (ET) with an aromatase inhibitor (AI) is the treatment of choice in post-menopausal patients with hormone receptor-positive early breast cancer (EBC). However, adverse events (AEs) often lead to treatment discontinuation. This analysis aimed to identify side-effects that lead to patients failing to persist with letrozole treatment.

Patients and methods: Post-menopausal hormone receptor-positive EBC patients starting ET with letrozole were enroled in EvAluate-TM, a non-interventional study. Information regarding treatment compliance and persistence was gathered in months 6 and 12. Persistence was defined as the time from 30 d after the start to the end of treatment. The influence on persistence of musculoskeletal syndrome, menopausal disorder, sleep disorder and other AEs within the first 30 d was analysed using Cox regression analyses.

Results: Among 3887 patients analysed, the persistence rate after 12 months was >85%. In all, 568 patients (14.6%) discontinued the treatment, 358 of whom (63.0%) did so only because of side-effects. The main AEs influencing persistence were musculoskeletal symptoms (hazard ratio [HR] 2.55; 95% confidence interval [CI], 1.90-3.42), sleep disorders (HR 1.95; 95% CI, 1.41-2.70) and other AEs (HR 2.03; 95% CI, 1.51-2.73). Menopausal disorder was not associated with non-persistence (HR 1.17; 95% CI, 0.74-1.84).

Conclusions: These results suggest that side-effects of AIs such as musculoskeletal syndrome and sleep disorder lead to ET discontinuation within the first treatment year in significant numbers of EBC patients. Compliance programmes adapted for subgroups that are at risk for early non-persistence might help to ensure the recommended therapy duration.

Clinical trials number: CFEM345DDE19.

Keywords: Adherence; Adverse events; Aromatase inhibitor; Breast cancer; Compliance; Endocrine treatment/therapy; Letrozole; Persistence; Side-effects.

PubMed Disclaimer

Publication types

LinkOut - more resources